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ABSTRACT
Background: Nasogastric tube position should be
checked every day by either aspirate pH or chest
radiography to prevent fatal misplaced feeding into the
lungs. Many patients do not have acidic gastric
aspirates and require daily chest radiographs. We
developed and validated a lipase test that was
compatible with non-acidic gastric aspirates.
Methods: We conducted evaluations of diagnostic test
accuracy at a teaching hospital in development and
validation stages. Development: We collected gastric
and lung aspirates from 34 consecutive patients. We
measured pH and human gastric lipase activity in the
laboratory. These data helped us develop the lipase
test. Ingenza Ltd (Roslin, Scotland) created tributyrin-
coated pH test paper, which human gastric lipase
converted into butyric acid, thus correcting false
negatives. Validation: We tested nasogastric feeding
tube aspirates from 36 consecutive patients with pH
and lipase tests, using chest radiography or trial by
use as the reference standard.
Results: Development: We demonstrated human
gastric lipase activity in the non-acidic stomach
aspirates. Validation: The accuracy of the lipase test
(sensitivity 97.2%, specificity 100%) was significantly
better than pH (sensitivity 65.7%, specificity 100%,
p<0.05).
Conclusions: When nasogastric tube stomach
aspirates were not acidic and pH was falsely negative,
the lipase test showed a true positive and was
significantly more accurate.
INTRODUCTION
Nasogastric tubes are commonly used to
assist enteral nutrition.1 The National Patient
Safety Agency issued guidelines recommend-
ing that aspirate pH is tested before every
feed and at least once every day to check
nasogastric tube position and prevent harm
from feeding into the lungs through a mis-
placed nasogastric tube. An acidic result
(pH≤5.5) indicates that the nasogastric tube
is correctly positioned in the stomach and
feeding is safe. If the result is not acidic
(pH>5.5), a chest radiograph is indicated to
check that the nasogastric tube is positioned
in the stomach and not in the lungs.2 3 No
tests other than pH and chest radiography
are reliable and currently recommended.4
However, up to 42% of hospital inpatients
receive antacid medications that render the
results of pH test paper falsely negative.5
The ideal solution would be a test that was
accurate despite non-acidic gastric aspirates,
safe, point-of-care and non-ionising. Other
authors have reported some success with
pH and magnetic-tipped nasogastric tube
stylets.6 7 The use of gastric enzymes in naso-
gastric tube position tests has been mooted,
but no evaluations of clinically viable proto-
types have been published.8
Human gastric lipase is an endogenous
gastric enzyme, which starts the digestion of
dietary triglyceride in the human stomach.9
Chief cells secrete human gastric lipase
Summary box
What is already known about this subject
▸ Nasogastric tube position should be checked
once a day to prevent the never event of mis-
placed feeding into the lungs.
▸ Only two tests are recommended: aspirate pH
and chest radiography.
▸ Many patients on acid-supressing medication
never have acidic gastric aspirates, which makes
the pH test falsely negative.
▸ It is not feasible to obtain daily chest radio-
graphs for these patients, especially in the com-
munity; therefore, there is no viable option.
What are the new findings
▸ We describe the development of a gastric
lipase-augmented nasogastric tube aspirate pH
test.
▸ We showed that lung aspirates have no lipase
activity.
▸ We then showed that false-negative pH results
were corrected by the lipase test, which signifi-
cantly improved accuracy.
How might it impact on clinical practice in
the foreseeable future?
▸ We intend to develop this prototype and create a
more viable daily nasogastric tube position test
that works for patients on acid suppression both
in hospital and in the community.
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entirely from the gastric fundus.10 11 It is not known for
certain if human lipase activity is present in the lungs.
Human gastric lipase is relatively stable and its produc-
tion, unlike the secretion of hydrochloric acid from
gastric parietal cells, is not affected by antacid medica-
tions.12 13 Production of human gastric lipase is well
developed at birth14 and is stimulated by pentagastrin
and a high-fat diet15 and reduces with age, but does not
diminish completely.11 One barrier to a single reagent
test is that human gastric lipase is inactivated by acidic
stomach contents and therefore is unsuitable as a means
of determining nasogastric tube position on its own. It
has been suggested that a combined test for pH incorp-
orating a gastric enzyme may be signiﬁcantly more
accurate than each in isolation.8 The objective of this
study was to develop and validate a nasogastric tube pos-
ition test that was compatible with non-acidic gastric
aspirates by utilising human gastric lipase to lower the
pH of gastric aspirates on pH test paper.
METHODS
Study design
We present two prospective studies. The development
phase explored human gastric lipase activity from
stomach and lung aspirates in the laboratory. The valid-
ation phase was a diagnostic test study that trialled the
lipase test versus pH to determine nasogastric tube pos-
ition reported in accordance with STARD guidelines.16
Setting
This research project was conducted in the UK at a single
tertiary-referral acute London teaching hospital between
2011 and 2012. Favourable opinions were obtained from
the UK National Health Service research ethics commit-
tees (Refs: 10/H0706/45 and 10/H0724/76).
Development phase
Recruitment consisted of consecutive adult patients
undergoing major upper-gastrointestinal surgery involv-
ing one-lung ventilation, a procedure that ensured
accurate collection of stomach and lung aspirates.
Patients known to have no gastric fundus (eg, previous
gastrectomy) were excluded because human gastric
lipase is exclusively produced by the fundus.11 All other
patients who gave valid consent to participate were
included. After the patient was anaesthetised, the con-
sultant anaesthetist inserted a nasogastric tube. The con-
sultant surgeon checked whether the tip of the
nasogastric tube was correctly positioned in the stomach
by palpation after gaining access to the abdominal cavity
through a laparotomy incision and before mobilising
any organs. This direct conﬁrmation of nasogastric tube
position represented the reference standard. After this
conﬁrmation, stomach aspirates were taken. In addition,
the consultant anaesthetist took lung aspirates under
direct vision by aspirating from the newly reinﬂated lung
near the end of the operation. We immediately labelled
the samples with anonymous codes and froze them to
−80°C ready for transport to the off-site laboratory. A
biochemist thawed the samples and tested pH and
human gastric lipase activity at the off-site laboratory.
The analysis was blinded. pH was measured by wetting
the pH test paper with an aspirate and waiting for 1 min
(Merck, New Jersey, USA, Ref: 1095840001). Human
gastric lipase activity was measured using the 718 STAT
Titrino (Metrohm, Herisau, Switzerland) using methods
that have already been described.13 A pH of ≤5.5 indi-
cated correct and >5.5 indicated incorrect nasogastric
tube position. Any human gastric lipase activity indicated
correct nasogastric tube position and no activity indi-
cated incorrect nasogastric tube position.
Design of lipase test
The results of the development phase informed the cre-
ation of the lipase test. A biochemist coated pH test
paper (Merck, New Jersey, USA, Ref: 1095840001) with
tributyrin (Ingenza Ltd, Roslin, Scotland). This substrate
produces an alcohol and butyric acid when metabolised
by human gastric lipase. We hypothesised that active
human gastric lipase in non-acidic nasogastric tube
stomach aspirates would create enough butyric acid to
change the pH on the lipase test paper to ≤5.5, thus cor-
recting false-negative results.
Validation phase
The accuracy of the lipase test was determined in the
validation phase. Recruitment consisted of consecutive
adult patients treated clinically with a nasogastric
feeding tube. Patients known to have no gastric fundus
(eg, previous gastrectomy) were excluded. All other
patients who gave valid consent to participate were
included. The reference standard test consisted of chest
radiography or trial by use if chest radiography was not
indicated. Consultant radiologists interpreted all chest
radiographs while blinded to the index test results.
Criteria for correct nasogastric tube position on the
chest radiograph included a straight vertical course near
the midline passing through the carina and not follow-
ing a bronchus with the tip below the diaphragm on the
same side as the gastric bubble. An aspirate from the
nasogastric tube was taken within 30 min of the chest
radiograph and there was no sign of nasogastric tube dis-
placement such as change in tube length in the inter-
vening time. If there were signs that the nasogastric tube
may have been displaced, for example, patient pulling
the tube, sticky plaster not securing the tube, length of
tube at nares changed, then repeat aspirate tests and
radiography were performed after the tube was resited.
Trial by use was used because the research ethics com-
mittee deemed it inappropriate to obtain additional
chest radiographs for the purpose of this study. Patients
who had trial by use already had the position of their
nasogastric tube satisfactorily conﬁrmed earlier by pH,
chest radiography or direct conﬁrmation during an
operation. All patients were followed up after their ﬁrst
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feed after entering the study had been administered and
again at discharge from the hospital to ensure that no
misplaced nasogastric tube feeding into the lung had
occurred during their admission (ie, aspiration pneumo-
nia). We tested the aspirate with the standard 0–6 pH
test paper with 0.5 increments and also with 2–9 pH
paper with 0.5 increments by wetting the test paper with
aspirate (BDH, VWR International Ltd, Leicester, UK,
Ref: 31505; and Merck, New Jersey, USA, Ref:
1095840001). We also simultaneously tested the aspirate
with the lipase test in the same way. Two study authors
(OA and MH) independently assessed the results of the
test papers, while blinded to the results of the reference
standard tests. The test papers were read at 1 min. A pH
of ≤5.5 indicated correct and >5.5 indicated incorrect
nasogastric tube position.
Statistics
In the development and validation phases, we compared
the accuracy of pH and lipase tests in the same partici-
pants with paired analyses.17 We required at least 10
patients for the development phase.18 For the validation
phase, we estimated that n=52 was required to rule out a
clinically signiﬁcant difference using pilot data (ﬁrst 20
patients, pH test paper accuracy was 65%, lipase test
accuracy was 100%, but 95% was used in the calculation,
α=0.05, power=80%).19 Planned interim analysis at the
end of the originally allotted study time period showed a
signiﬁcant difference, and therefore recruitment was not
extended beyond 36 patients.
RESULTS
Development phase
Participants
We recruited 36 consecutive patients who underwent
upper-gastrointestinal surgery between 2011 and 2012.
Two patients were not included in the analysis, because
one patient withdrew consent and another patient had
an inoperable tumour and the position of their nasogas-
tric tube could not be conﬁrmed during the operation.
Therefore, data from 34 patients were included in the
analysis, 23 men and 11 women. The median age of par-
ticipants was 68 years (range 44–82). We obtained gastric
aspirates from 32 patients (2 patients had dry gastric
aspirates) and lung aspirates from 23 patients (11
patients had dry lung aspirates). Twenty-two patients
(65%) were taking antacid medication (12 were taking
omeprazole, 7 were taking lansoprazole and 3 were
taking esomeprazole). We excluded no data from the
analysis. There were no indeterminate or outlier results.
Stomach samples
The pH of the 32 stomach samples ranged from 1 to 8.5
with a mean of 4.4. 19 (59%) of the stomach samples
had a pH of 5.5 or less, which would indicate correct
placement of a nasogastric tube. Human gastric lipase
activity was present in 21 (66%) of the stomach samples
and all of the samples between pH 3 and 8. Human
gastric lipase activity was not present in samples that
were more acidic than pH 3 and was also not present in
a single alkaline sample at pH 8.5. This was the most
alkaline sample and human gastric lipase activity was
present in samples at pH 8. Crucially, 31 (97%) of the
stomach samples had either a pH of 5.5 or less and/or
human gastric lipase activity. Therefore, this indicated
that a combined pH and human gastric lipase test could
be more accurate than pH alone.
Lung samples
The pH of the 23 lung samples ranged from 6 to 8.5
with a mean of 6.9. None of the lung samples had a pH
of 5.5 or less, which could have resulted in misplaced
nasogastric tube feeding into the lung on pH criteria.
Human gastric lipase activity was present in none of the
lung samples, which was essential to the viability of a
human gastric lipase-based test.
Validation phase
Participants
We approached 46 consecutive ward patients who were
treated clinically with nasogastric tubes between 2011
and 2012. One patient could not be recruited because
they had a previous gastrectomy. Nine of the recruited
patients were not included in the analysis because their
nasogastric tube aspirates were dry. Therefore, data from
36 patients were included in the analysis, which included
27 men and 18 women. The median age of the partici-
pants was 67 years (range 22–88). In total, 38 patients
(84%) were taking antacid medication (17 were taking
omeprazole, 20 were taking lansoprazole and 1 was
taking esomeprazole).
Diagnostic accuracy
Table 1 shows a summary of the results. All measure-
ments were made twice, independently, by two assessors
(OA and MB) and were always in agreement with one
Table 1 Diagnostic accuracy results from the validation
phase
pH + + − −
Lipase test True status + − + −
+ + 23 11
+ − 0 0
− + 0 1
− − 0 1
pH (%) Lipase test (%)
Sensitivity 65.7 97.2
Specificity 100 100
Positive predictive value 100 100
Negative predictive value 7.7 50
+, Indicates correct nasogastric tube placement; −, indicates
incorrect nasogastric tube placement.
Anderson O, Carr R, Harbinson M, et al. BMJ Open Gastro 2016;3:e000064. doi:10.1136/bmjgast-2015-000064 3
Open Access
another. We excluded no data from the analysis. There
were no indeterminate or outlier results. Overall, the
accuracy of the lipase test was signiﬁcantly greater than
pH (extended McNemar’s test x2=11 with 2 df, p<0.05).
The sensitivity of the lipase test was signiﬁcantly greater
than pH (x2=9.091 with 1 df, p<0.05). The 95% conﬁ-
dence interval for the difference between the sensitiv-
ities was 17.3% to 47.5%.17
DISCUSSION
In the development study, we determined pH and
human gastric lipase activity in stomach and lung aspi-
rates. We found human gastric lipase activity in the
stomach when the pH was not acidic (pH>5.5), which
conﬁrmed that a combined pH and lipase test might be
viable and more accurate than each in isolation. We then
incorporated tributyrin, a substrate to human gastric
lipase, onto pH test paper. Tributyrin is metabolised by
human gastric lipase to form butyric acid. This acid
lowers pH and corrects false-negative results from gastric
aspirates that are not acidic. We also showed that there is
no human gastric lipase activity in lung aspirates, another
new and crucial ﬁnding, because if there were any
human gastric lipase activity in the lung, the lipase test
could produce catastrophic false positives. In the second
study, we examined the lipase test on aspirates from ward
patients with nasogastric feeding tubes and demonstrated
that it had signiﬁcantly improved accuracy at determining
nasogastric tube position when compared with pH.
We addressed an important unmet need in this trans-
lational research project with a novel innovative solution
that can be clinically implemented and result in tangible
beneﬁts to patients, healthcare workers and organisa-
tions. We used robust methods and reported these in
accordance with the STARD, QUADAS-2 and QAREL
quality checklists for studies of diagnostic tests.16 20 21 In
the validation phase, we included a spectrum of partici-
pants that is representative of the patients who will
receive the test in practice. Very few patients were
excluded from the study and we detailed the reasons in
each case. The reference standard tests used in both
studies were likely to classify the position of the nasogas-
tric tube correctly and the index tests were performed
very close to the time of the reference standard tests.
The index test did not form part of the reference stand-
ard tests. No patients were lost to follow-up. In the valid-
ation phase, assessment of the index tests was
independent, blinded and random with good inter-rater
reliability and with the same clinical data as would be
available were the test performed in practice. There
were no uninterpretable, indeterminate and intermedi-
ate results or withdrawals after entering the study.
We could not include patients who were unable to
give valid consent. This included some patients in the
acute phases of a stroke. We did include patients with
stroke who could give valid consent. Therefore, we
believe that the potential spectrum bias introduced by
not including patients who cannot give valid consent
does not affect the generalisability of the results. It was
deemed unethical to perform additional research chest
radiographs on patients who did not require them clinic-
ally by an independent research ethics committee, as
trial by use as described in the methods provided an
equivalent reference standard to chest radiography and
more accurately represented clinical practice. The lipase
test and all aspirate nasogastric tube position checks
could produce a false positive result if fresh gastric con-
tents were aspirated from the lungs. This diagnosis
might be missed in patients with clinically silent aspir-
ation pneumonia such as those in a coma. Therefore, we
support the use of chest radiographs in patients at risk
of silent aspiration pneumonia to check both nasogastric
tube position and for radiological signs of the diagnosis.
Up to 42% of hospital inpatients receive antacid medi-
cations that render the results of pH test paper falsely
negative.5 According to the guidelines, these patients
require a chest radiograph every day. Daily chest radiog-
raphy is undesirable due to radiation, cost, time and
inconvenience and is inaccessible once the patient
leaves the hospital. The ideal solution would be a test
that was accurate despite non-acidic gastric aspirates,
safe, point-of-care, intuitive and non-ionising. Other
authors have reported success with pH and magnetic-
tipped nasogastric tube stylets.6 7 These have not been
widely adopted because they are operator dependent,
requiring training of specialist teams that do not repre-
sent the majority of end-users. The lipase test is a viable
daily nasogastric tube position check for patients in hos-
pital and in the community. Patients with no functioning
gastric fundus to secrete human gastric lipase will not
beneﬁt. The lipase test will reduce reliance on chest
radiographs. A reduction in reliance on chest radio-
graphs is desirable to minimise the delay to start
feeding, exposure to radiation, cost, burden on services
and misinterpretation. The National Patient Safety
Agency received reports of 32 deaths and 80 severe
harms associated with feeding into the lungs through
misplaced nasogastric tubes between 2002 and 2010.2 3
Misinterpretation of chest radiographs was the most
common reason for harmful misplaced nasogastric tube
feeding into the lungs.1 22
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